Clinical Trials Directory

Trials / Completed

CompletedNCT02409082

Alzheimers Disease and Neuromarkers in Patients With Acute Hip Fractures

The Presence of Pre-Alzheimers/Alzheimers Disease (AD) and Neuromarkers Related to Morbidity/Mortality in Patients With Acute Hip Fractures

Status
Completed
Phase
Study type
Observational
Enrollment
400 (actual)
Sponsor
Sahlgrenska University Hospital · Academic / Other
Sex
All
Age
Healthy volunteers
Not accepted

Summary

The investigators explore the presence of AD factors beta-amyloid and tau in CSF and plasma to verify AD diagnosis in patients with acute hip fracture. Clinical dementia test is performed prior to operation. Blood samples and CSF samples are collected at surgery and blood samples are collected postoperatively at intervals. Mortality is assessed at 30 days, 3 months and 1 year. Morbidity is assessed at , 3 months and \>1 year. Neuromarkers specifically addressing the inflammatory component are to be analyzed and correlated to outcome together with AD markers, as above.

Detailed description

The hypotheses explored in this investigation is that patients being pre-AD or having AD have worse prognosis following an acute hip fracture. This has been demonstrated in retrospective studies. In this study we admit all patients with a hip fracture planned tro receive a spinal anesthesia. Our golden standard of anesthesia in this patient cohort. Preoperatively Clinical Dementia Score is assessed after study inclosure. At the performance of the spinal dosage is standardized. Prior to giving this 5 ml of CSF is collected and blood is collected. Blood is then collected at intervals up until day 3 postoperatively. We plan to analyze beta-amyloid and tau in CSF and plasma to verify AD diagnosis in patients with acute hip fracture. Mortality is assessed at 30 days, 3 months and 1 year. Morbidity is assessed at, 3 months and \>1 year. Neuromarkers specifically addressing the inflammatory component are to be analyzed and correlated to outcome together with AD markers, as above.

Conditions

Timeline

Start date
2013-09-11
Primary completion
2015-06-22
Completion
2016-12-20
First posted
2015-04-06
Last updated
2017-04-26

Locations

1 site across 1 country: Sweden

Source: ClinicalTrials.gov record NCT02409082. Inclusion in this directory is not an endorsement.